It’s been a big month in the news department for 1DegreeBio, a portfolio company of ours that aids researchers in sourcing and reviewing antibodies. The Toronto-based start-up announced yesterday that it had closed its Series B round of funding, led by a follow-on investment by Digital Science. Philip Armstrong, CEO of Jovian Capital Corporation and 1DegreeBio senior management also participated in the round.

The company has experienced significant growth over the past year, growing its user base from 23,000 to over 75,000 users, and building its product catalog from 400,000 listings to more than 800,000. 

From their funding press release:

“1DegreeBio has proven a tremendously valuable resource to the research community,” said Timo Hannay, Managing Director, Digital Science. “We are pleased to have them as part of the Digital Science family, and look forward to seeing even more developments in their offering in the year to come.”

The announcement follows the launch of their Epigenetics Portal, launched on June 4 as a place where epigenetics researchers can find targets, tools and product data specific to their research. As of last week, validation data and community reviews for an initial set of 10 renewable recombinant antibodies for epigenetic targets can be found on These antibodies are important due to their involvement in a wide variety of chronic diseases, and are the targets of a new field of drug discovery. 

A massive congratulations to 1DegreeBio for their recent successes, and do stay tuned for more. 

For more information on their recent funding round or the Epigenetics Portal visit their press page at